Media ReleasesAirXpanders Inc

View All AirXpanders Inc News


AirXpanders, Appendix 4C - Quarterly Cash Flow Report and Business Update

Highlights for the quarter ended 30 September 2017

• Revenue increased to US$1.2 million compared to US$0.2 million in Q3 2016; driven primarily by U.S. sales growth

• U.S. unit sales grew 108% compared to Q2 2017

• AeroForm® available in more than one hundred and twenty (120) hospitals across the US

• Third party contract manufacturer in Costa Rica validated and on-line for higher capacity production

• Closed US$15 million minimally-dilutive debt agreement with Oxford

• Cash and short-term investments balance as of 30 September 2017 of US$30.8 million

Palo Alto, CA, United States – AirXpanders, Inc. (ASX:AXP), a medical device company focused on the design, manufacture, sale and distribution of the AeroForm® Tissue Expander System, today released its Appendix 4C – Quarterly Cash Flow report for the quarter ended 30 September 2017.


To view Report please download PDF attached:
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.